FDA (Food and Drug Administration)

What are the stages of FDA approval?

The U.S. Food and Drug Administration (FDA) approval process for medical devices involves several stages, each designed to ensure the safety, efficacy, and quality of medical devices entering the market. The specific approval pathway depends on the device's classification, which is determined by its risk level. Here’s a general overview of the typical stages involved in the FDA approval process:

• Pre-submission Phase
• Pre-Submission Meeting: Manufacturers can request a meeting with the FDA to receive guidance before submitting their application. This is an opportunity to discuss any questions related to regulatory requirements, clinical study design, and other aspects of the approval process.
• Submission Phase
• Determine the Appropriate Regulatory Pathway: Depending on the device’s classification and characteristics, manufacturers choose the appropriate regulatory pathway, such as:
• 510(k) Clearance (for devices that are substantially equivalent to a device already on the market)
• De Novo Classification (for low-to-moderate risk devices that are novel and have no equivalent on the market)
• Premarket Approval (PMA) (for high-risk devices that require evidence of safety and effectiveness)
• Submission of Application: The manufacturer submits the required documentation, which may include detailed descriptions of the device, labeling, instructions for use, any data from preclinical and clinical studies, and a plan for post-market surveillance.
• Review Phase
• FDA Review: The FDA reviews the submitted application to ensure it meets all regulatory standards. The complexity and duration of the review process vary depending on the device’s risk and the pathway:
• 510(k) reviews typically take about 90 days
• De Novo requests may take about 120 days
• PMA applications involve a more extensive review, usually within 180 days, and often require multiple rounds of submission and review
• FDA Decision: The FDA can approve the application, request additional information (leading to further review cycles), or deny the application.
• Post-Approval Phase
• Manufacturing and Labeling Inspections: Before the device can be marketed, the FDA may inspect the manufacturing facilities to ensure compliance with quality standards.
• Post-Market Surveillance: Once the device is on the market, manufacturers must monitor its performance and report any adverse events or other findings that could affect its safety or effectiveness. This might include conducting post-market studies as mandated by the FDA.
• Periodic Reporting: Manufacturers must submit periodic reports to the FDA, including updates on ongoing clinical trials and any changes to the device or its manufacturing process.

How many drugs are classified by the FDA?

The U.S. Food and Drug Administration (FDA) classifies drugs based on various characteristics, including their therapeutic effectiveness, chemical type, and application method. However, when discussing "classification," it can refer to several different categorization systems used by the FDA. Here are the main ways in which drugs are classified:

• Prescription vs. Over-the-counter (OTC): This is a primary classification based on whether a drug can be safely used without a healthcare provider's supervision. Prescription drugs require a doctor's prescription due to factors like potential side effects, toxicity, or the need for professional monitoring. Over-the-counter drugs are deemed safe and effective for use by the general public without a prescription.
• Controlled Substance Schedules: Drugs with potential for abuse are further classified into five schedules under the Controlled Substances Act (CSA) based on their acceptable medical use and abuse or dependency potential:
• Schedule I: Drugs with no currently accepted medical use and a high potential for abuse (e.g., heroin, LSD).
• Schedule II: Drugs with a high potential for abuse, with use potentially leading to severe psychological or physical dependence (e.g., Vicodin, cocaine, methamphetamine).
• Schedule III: Drugs with a moderate to low potential for physical and psychological dependence (e.g., Tylenol with codeine, ketamine).
• Schedule IV: Drugs with a low potential for abuse and low risk of dependence (e.g., Xanax, Valium).
• Schedule V: Drugs with lower potential for abuse than Schedule IV and consist of preparations containing limited quantities of certain narcotics (e.g., cough preparations with less than 200 milligrams of codeine per 100 milliliters).
• Drug Categories Based on Use or Treatment: The FDA also classifies drugs based on the conditions they treat, such as antipyretics (for fever), analgesics (for pain), antimalarial drugs, antibiotics, and more.
• Regulatory Pathways: Drugs are also classified based on the regulatory pathway for approval, such as new drug applications (NDAs), generic drug applications (ANDAs), or biologic license applications (BLAs) for biologics.
• Pregnancy and Lactation Labeling: The FDA uses a classification system to indicate the safety of using drugs during pregnancy and lactation, which categorizes the potential risk to fetuses and breastfeeding infants.
• Orphan Drugs: Drugs used to treat rare diseases affecting fewer than 200,000 people in the U.S. are classified as orphan drugs, which can qualify for specific incentives to encourage their development.